Comparison of antiangina therapies in patients with coronary heart disease in China: study protocol for a multicentre, retrospective, hospital system-based study.

ABSTRACT:

Introduction

China has the largest number of patients with coronary heart disease (CHD) in the world. Numerous pharmacological strategies are available for CHD in routine clinical practice. CHD-induced angina pectoris affects patients' quality of life and is a key predictor of prognosis. This study will compare the effectiveness of different antiangina treatments, particularly ATP-sensitive potassium channel (K_ATP) activators, in the Central China District. This proposal underpins the first comparison of antiangina therapies in patients with CHD in China using a multicentre, retrospective, hospital system-based assessment.

Methods and analysis

This retrospective real-world study will assess the largest hospital databases in Wuhan City in Central China to evaluate

SUBMITTER: Li P 

PROVIDER: S-EPMC7925860 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature